Cantor Fitzgerald analyst Elemer
Piros notes that PolarityTE was granted a patent by the Canadian Intellectual Property Office related to methods for development and use of minimally polarized function cell micro-aggregate units.
Cantor Fitzgerald analyst Elemer
Piros reiterated an Overweight rating and $229 price target.
The interest towards those colour terms was incipient already at the end of the 19th century, when a medical scientist Istvan Csapodi published an article "Voros es
piros" (1899).
(XAV900) SMALL CAP DRUG DEVELOPMENT COMPANIES: ELEMER
PIROS - RODMAN & RENSHAW INC.
Cantor Fitzgerald analyst Elemer
Piros reiterates an Overweight rating on Tocagen with a $28 price target after the company announced that the Phase 3 trial of Toca 511 and Toca FC in recurrent high-grade glioma will continue without modification.
(TAN901) INVESTMENT OPPORTUNITIES IN BIOTECHNOLOGY: ELEMER
PIROS - RODMAN & RENSHAW INC.
Cantor Fitzgerald analyst Elemer
Piros says PolarityTE's presentation yesterday highlighted differentiated case studies in which SkinTE was an effective treatment in restoring the regenerative properties of skin.
In a study highlighted by the International Wound Journal, PolarityTE's SkinTE was able to re-epithelialize the skin, which in turn led to complete healing and improvement in pain, of a patient with a greater than two year old large, chronic wound that failed numerous split-thickness skin grafts and treatments, Cantor Fitzgerald analyst Elemer
Piros tells investors in a research note.
Cantor Fitzgerald analyst Elemer
Piros raised his price target for uniQure (QURE) to $81 from $68 after Roche (RHHBY) acquired Spark Therapeutics (ONCE) for $4.8B.
Cantor Fitzgerald analyst Elemer
Piros points out that in addition to its Q3 financial results today, Galmed Pharmaceuticals provided timelines for a Phase 3 initiation in mid-2019 and manufacturing of Phase 3 active pharmaceutical ingredients in Q4.
Apellis Pharmaceuticals last night reported that it initiated a temporary pause in dosing for its Phase 3 geographic atrophy program due to the occurrence of non-infectious inflammation associated potentially with a single lot of APL-2 drug, Cantor Fitzgerald analyst Elemer
Piros tells investors in a research note.
Cantor Fitzgerald analyst Elemer
Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October.